| P50 | author | Peter Boyle | Q2074086 |
| P2093 | author name string | Freddie C Hamdy | |
| | Jean-Pierre Raynaud | |
| | Frans Debruyne | |
| | Pierre Teillac | |
| | Gary Koch | |
| | Remigio Vela-Navarrete | |
| | Paul Perrin | |
| | Fernando Calais Da Silva | |
| | Jay G Gillenwater | |
| P2860 | cites work | A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction | Q28377593 |
| | Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review | Q31973506 |
| | Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia | Q32064218 |
| | Phytotherapy in the treatment of benign prostatic hyperplasia: an update | Q33591029 |
| | The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association | Q33846043 |
| | Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia | Q33895865 |
| | Medical therapy for benign prostatic hyperplasia: a review of the literature | Q33946113 |
| | Human prostatic steroid 5α-reductase isoforms—A comparative study of selective inhibitors | Q34296942 |
| | Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies | Q34465183 |
| | Tamsulosin : A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Symptomatic Benign Prostatic Hyperplasia | Q39358923 |
| | Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients | Q39461920 |
| | Benign prostatic hyperplasia. Medical and minimally invasive treatment options | Q40395290 |
| | alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia | Q40403192 |
| | Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia | Q41217704 |
| | A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia | Q42531516 |
| | Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group | Q42613682 |
| | Determination of prostate volume by transrectal ultrasound | Q44552568 |
| | The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group | Q45335490 |
| | Reproducibility and clinical and concurrent validity of the MSF-4: a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia | Q47597293 |
| | Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flow. | Q52900720 |
| | Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. | Q53351995 |
| | Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group | Q71724801 |
| | Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group | Q74605816 |
| | Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group | Q74605818 |
| | A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group | Q77449251 |
| | Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH | Q78040597 |
| | Medical management of benign prostatic hyperplasia | Q78092507 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostatic hypertrophy | Q506659 |
| P304 | page(s) | 497-506; discussion 506-7 | |
| P577 | publication date | 2002-05-01 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study | |
| P478 | volume | 41 | |